Pan-Resistant <i>Acinetobacter</i> <i>baumannii</i> Mediastinitis Treated Successfully with Tigecycline: A Case Report

Tekçe, Ayşe Yasemin Tezer; Erbay, Ayşe; Çabadak, Hatice; Yağcı, Serap; Karabiber, Nihal; Şen, Süha

doi:10.1089/sur.2009.063

Cited by 13 publications

(10 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although A. baumannii is resistant to many antimicrobial agents, tigecycline and colistin could be alternative drugs for the treatment of MDR A. baumannii infection [7][8][9]18]. For testing against Acinetobacter spp., CLSI and EUCAST guidelines are available for colistin only by the BMD method, which is impracticable in clinical laboratories, and no testing method and interpretative breakpoint is available for tigecycline.…”

Section: Discussionmentioning

confidence: 99%

“…Although MDR A. baumannii isolates are resistant to almost all available agents, they are often susceptible in vitro to tigecycline and colistin [2][3][4][5]. Both tigecycline and colistin are active against many MDR Gram-negative bacteria, especially in the treatment of serious infections [3,[6][7][8][9]. Despite potential use in clinical practice, a standardised susceptibility testing method and interpretative breakpoints for tigecycline against A.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii clinical isolates, including multidrug-resistant isolates

Piewngam

Kiratisin

2014

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii clinical isolates, including multidrug-resistant isolates

Piewngam

Kiratisin

2014

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…Tekçe AY et al 2011 [268] Case report of a "pan-resistant" A. baumannii, susceptible to colistin and tigecycline. The patients was successfully treated with tigecycline.…”

Section: Rodrigues Ac Et Al 2011 [264]mentioning

confidence: 99%

Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options

Karakonstantis

Kritsotakis

Gikas

2019

Journal of Antimicrobial Chemotherapy

105

115

View full text Add to dashboard Cite

Background The literature on the epidemiology, mortality and treatment of pandrug-resistant (PDR) Gram-negative bacteria (GNB) is scarce, scattered and controversial. Objectives To consolidate the relevant literature and identify treatment options for PDR GNB infections. Methods A systematic search in MEDLINE, Scopus and clinical trial registries was conducted. Studies reporting PDR clinical isolates were eligible for review if susceptibility testing for all major antimicrobials had been performed. Characteristics and findings of retrieved studies were qualitatively synthesized. Results Of 81 studies reviewed, 47 (58%) were published in the last 5 years. The reports reflected a worldwide dissemination of PDR GNB in 25 countries in 5 continents. Of 526 PDR isolates reported, Pseudomonas aeruginosa (n=175), Acinetobacter baumannii (n=172) and Klebsiella pneumoniae (n=125) were most common. PDR GNB were typically isolated in ICUs, but several studies demonstrated wider outbreak potential, including dissemination to long-term care facilities and international spread. All-cause mortality was high (range 20%–71%), but appeared to be substantially reduced in studies reporting treatment regimens active in vitro. No controlled trial has been performed to date, but several case reports and series noted successful use of various regimens, predominantly synergistic combinations, and in selected patients increased exposure regimens and newer antibiotics. Conclusions PDR GNB are increasingly being reported worldwide and are associated with high mortality. Several treatment regimens have been successfully used, of which synergistic combinations appear to be most promising and often the only available option. More pharmacokinetic/pharmacodynamic and outcome studies are needed to guide the use of synergistic combinations.

show abstract

“…Since the establishment of the Xiangyang Hospital in 1992, we have observed the emergence of Acinetobacter baumannii and currently there are infection cases of pan-resistant Acinetobacter baumannii ( 8 – 10 ). The challenge for treating pulmonary infection with pan-resistant Acinetobacter baumannii involves selection of medication ( 11 ).…”

Section: Discussionmentioning

confidence: 99%

Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection

Pan

Liu

Shou-gui

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Bacterial infections are common but have become increasingly resistant to drugs. The aim of the present study was to examine the combined treatment of traditional Chinese and Western medicine in 30 cases of pulmonary infection with multidrug resistant Acinetobacter baumannii. Patients were divided into groups A and B according to drug treatments. Cefoperazone or sulbactam and tanreqing were administered in group A, and cefoperazone or sulbactam in group B. The curative effect and prognosis of the two groups were recorded and the remaining treatments were performed routinely in the clinic. For the combined therapy group, which was administered sulperazone and tanreqing, 8 patients were recovered, 6 patients had significant effects, 3 patients exhibited some improvement and 1 patient had no response. One of the patients did not survive after 28 days. By contrast, there were 4 patients that were successfully treated, 3 patients with significant effects, 2 patients with some improvement and 2 patients had no response in the sulperazone group, and 4 patients did not survive after 28 days. In conclusion, the combined therapy of cefoperazone or sulbactam supplemented with tanreqing was identified to be more effective than cefoperazone or sulbactam as monotherapy, for treating multidrug resistant Acinetobacter baumannii.

show abstract

Pan-Resistant Acinetobacter baumannii Mediastinitis Treated Successfully with Tigecycline: A Case Report

Abstract: Surgical source control along with effective antibiotics is essential in the treatment of mediastinitis. Tigecycline has the potential to be an option for pan-resistant A. baumannii mediastinitis.

Cited by 13 publications

References 12 publications

Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii clinical isolates, including multidrug-resistant isolates

Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii clinical isolates, including multidrug-resistant isolates

Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options

Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection

Contact Info

Product

Resources

About